A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma ...

As of March 31, 2025, Tonix had $131.7 million of cash and cash equivalents, compared to $98.8 million as of December 31, 2024. Net cash used in operations was approximately $16.6 million for first ...

Atea defines working capital as current assets less current liabilities. See the Company's condensed consolidated financial ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients ...

Alcohol's negative effect on women's working memory is somewhat mitigated when their estrogen levels are higher, a novel ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

People with type 2 diabetes don’t make an adequate amount of insulin to manage their blood sugar. Stem cell therapy may ...

Scientists have discovered a promising new therapy for resistant high blood pressure, leading to a 15-point drop in systolic ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...

Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET. Company Participants. Stephanie Fagan - Chief Corporate Affairs Officer Rob Bar ...